Key Highlights
- Dr. Julie Jordan appointed as Chief Medical Officer of Neurogene Inc., bringing over 20 years of industry and clinical experience.
- Expertise in global clinical trials and gene therapy, particularly in central nervous system disorders.
- Previously served as Chief Medical Officer at Homology Medicines, with significant contributions in gene therapy and gene editing for rare diseases.
Source: Business Wire
Notable Quotes
- “A proven leader with deep clinical and regulatory expertise to advance pioneering medicines through development, we are thrilled to welcome Julie to the team.” – Rachel McMinn, Ph.D., Founder and CEO at Neurogene
- “Leveraging its proprietary EXACT gene regulation technology, Neurogene is at the forefront of developing novel genetic medicines with the potential to overcome the challenges that have limited the use of conventional gene therapies for the treatment of rare neurological conditions.” – Dr. Julie Jordan, M.D., Chief Medical Officer at Neurogene
SoH's Take
The appointment of Dr. Julie Jordan as Chief Medical Officer at Neurogene Inc. marks a significant milestone in the company’s pursuit of innovative treatments for rare neurological diseases. Dr. Jordan’s extensive experience in gene therapy and clinical trials, especially in the realm of central nervous system disorders, positions her as a pivotal figure in driving forward Neurogene’s ambitious pipeline. Her prior accomplishments in leading clinical developments and navigating regulatory landscapes at Homology Medicines demonstrate her capability to spearhead complex projects and initiatives.
With Neurogene’s focus on overcoming the limitations of conventional gene therapy, particularly through its EXACT transgene regulation platform technology, Dr. Jordan’s leadership could accelerate the development of groundbreaking treatments. Her history of successful collaboration with patient advocacy groups and key opinion leaders also underscores the importance of community and patient-centric approaches in the pharmaceutical industry.
Overall, Dr. Jordan’s appointment is a clear indicator of Neurogene’s commitment to advancing genetic medicine and addressing the unmet needs of patients with rare neurological conditions. Her expertise will likely be a driving force in realizing the company’s vision of transforming the treatment landscape for these challenging disorders.
